Research within the Webb group focuses on the occurrence of metals in medicine, as either the therapeutic agent or the target for therapy. Specifically, protein interactions have been observed to be central in either the pathology of several diseases following an interaction with endogenous metal ions, thereby becoming the target for therapy, or in the transportation of metallotherapeutics to their site of action. We are currently investigating several metal-protein interactions, to provide new leads for therapeutic development. For more information on current research and potential opportunities, please visit my personal research webpage.
University of California Berkeley
Ph D Chemistry
Simon Fraser University
Burnaby, BC, Canada
Mount Allison University
Sackville, NB, Canada
Journal Article, Academic Journal
Webb, M., & Walsby, C. Albumin binding and ligand-exchange processes of the Ru(III) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy. Dalton Transactions 44 (2015): 17482-17493.
Jones, M., Mu, C., Wang, M., Webb, M., Walsby, C., & Storr, T. Modulation of the Aβ peptide aggregation pathway by KP1019 limits Aβ-associated neurotoxicity. Metallomics 7 (2014): 129-135.